Evogene

Evogene said its strategic refocus on ChemPass and AI-driven small‑molecule discovery has yielded six drug collaborations, integration with Google Cloud and expanded virtual chemical space to 110 billion molecules. Management reported a leaner headcount (117 to 38), proceeds from Lavie Bio and Biomica transactions, and a reduced cash burn guidance of $8.5–9.5 million for 2026 with $9.3 million in cash at June 30. Second‑quarter net loss narrowed to about $1.8 million (Q2 2025: $4.7 million) while H1 revenues fell to $0.7 million; management said continuity of the current board is needed amid a dissident campaign and plans to add two new directors if re‑elected. » Mais em finance.yahoo.com

Evogene reported a net loss of about $1.8 million for Q2 2026 versus $4.7 million a year earlier, with revenue falling to roughly $0.3 million. The company highlighted lower cash burn (Q2 about $2.1 million; full-year guidance $8.5–9.5 million) and a restructuring that reduced headcount to 38 employees. Evogene is expanding its AI platform and has several collaborations, but continues to face low, irregular revenue and a need for financing. The stock fell 7.77% in trading to $165.10 as investors weighed the revenue decline and potential dilution more heavily than the earnings improvement. » Mais em de.investing.com

Evogene and the Blavatnik Center for Drug Discovery at Tel Aviv University are launching a program to support Israeli academic projects in small‑molecule drug discovery. The collaboration combines Evogene’s generative AI platform ChemPass for computational chemistry with the BCDD’s experimental infrastructure and offers selected projects access to an integrated design‑make‑test‑analyze workflow. Ramot brokered the partnership; Evogene will handle molecular design and optimization, and the BCDD will perform experimental validation and screening. » Mais em de.investing.com